(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
The Best Traditional Music Arrangers in History- ‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- US bishops officially ban gender-affirming care at Catholic hospitals
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- Vote in favor of the juice that you love for its medical advantages!
